At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
VX-745drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Multiple Dose Clinical Pharmacology Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) or With Mild AD
In Brief
A Phase 2 clinical trial evaluating VX-745 for Alzheimer's Disease. Completed, enrolled 16 participants across 1 site.
Detailed Summary
This study will assess the effects of VX-745 on markers of disease in the central nervous system of patients with MCI due to AD or with mild AD. The study will also evaluate the safety and tolerability of VX-745 in these patients during 6 weeks of dosing, as well as the plasma and cerebrospinal fluid concentrations of VX-745 during dosing.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartApr 2015
First PostedApr 2015
Primary CompletionSep 2016
Study CompletionNov 2016
TodayJul 2026
First PostedApr 22, 2015
Enrollment StartApr 1, 2015
Primary CompletionSep 1, 2016
Study CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.2 years ago
Interventions
VX-745drug
Orally-active P38 MAP kinase alpha-selective inhibitor